Use Acetazolamide in the Complex Therapy of Alzheimer’s Disease

Published: 21 November 2023| Version 1 | DOI: 10.17632/4hcmcwzxfh.1


Background Impaired glymphatic clearance is one of the causes of Alzheimer’s disease. Acetazolamide is a drug that affects the normalization of glymphatic clearance. Methods We followed four women aged 65-70 years with a diagnosis of Alzheimer’s disease in 2019-2021. They were treated in the unit according to Alzheimer’s disease treatment standards. During periodic examination by an ophthalmologist, they were diagnosed with first-stage glaucoma (initial) - a blind spot interfering with normal peripheral vision and a deepening of the optic disc in the central zone were identified. For a glaucoma treatment, they were prescribed Acetazolamide 125 mg once a day in the morning for 7 days with weekly monitoring of intraocular pressure. They also received Asparkam, 1 tablet, 3 times a day during Acetazolamide administration to prevent a deficiency of potassium ions in the body. On days 12-14 after normalization intraocular pressure, Acetazolamide administration was discontinued. To monitor the dynamics of cognitive impairment, patients on the unit underwent Trail Making Test Parts A & B paper-pencil versions every month. Results Before glaucoma treatment, the patients' Trail Making Test Parts A speeds were 84, 87, 90, and 92 seconds. The speed of Part B was 270, 300, 293, and 305 seconds. After two weeks of glaucoma treatment, patients again completed the Trail Making Test Parts A & B paper-pencil versions. The patients' speeds for Part A were 60, 68, 63, and 70 seconds. The speeds in Part B were 180, 190, 217, and 194 seconds. Conclusion Administration of Acetazolamide has a positive effect on patients with cognitive deficits and can be successfully used as part of the complex therapy of Alzheimer’s disease. Volume18, IssueS9 Supplement: Dementia Care Practice (Descriptive) December 2022 e059982 Related Information Recommended Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia Rosalinde E.R. Slot, Sietske A.M. Sikkes, Johannes Berkhof, Henry Brodaty, Rachel Buckley, Enrica Cavedo, Efthimios Dardiotis, Francoise Guillo-Benarous, Harald Hampel, Nicole A. Kochan, Simone Lista, Tobias Luck, Paul Maruff, José Luis Molinuevo, Johannes Kornhuber, Barry Reisberg, Steffi G. Riedel-Heller, Shannon L. Risacher, Susanne Roehr, Perminder S. Sachdev, Nikolaos Scarmeas, Philip Scheltens, Melanie B. Shulman, Andrew J. Saykin, Sander C.J. Verfaillie, Pieter Jelle Visser, Stephanie J.B. Vos, Michael Wagner, Steffen Wolfsgruber, Frank Jessen, the Alzheimer's Disease Neuroimaging Initiative, the DESCRIPA working group, the INSIGHT-preAD study group, SCD-I working group, Wiesje M. van der Flier Alzheimer's & Dementia

Files not available for this dataset

This contains only metadata

Steps to reproduce

Indicate the subject disciplines your dataset relates to, to help others find your data.